Garfield E. The 1982 John Scott Award goes to Jack Fishman and Harold Blumberg for synthesis and investigations on naloxone. Essay Inf Sci. 1983;6:121–30.

Google Scholar 

Foldes FF, Duncalf D, Kuwabara S. The respiratory, circulatory, and narcotic antagonistic effects of nalorphine, levallorphan, and naloxone in anaesthetized subjects. Can Anaesth Soc J. 1969;16(2):151–61.

Article  CAS  PubMed  Google Scholar 

Foldes FF, Lunn JN, Moore J, Brown IM. N-Allylnoroxy-morphone: a new potent narcotic antagonist. Am J Med Sci. 1963;245:23–30.

CAS  PubMed  Google Scholar 

Skolnick P. Treatment of overdose in the synthetic opioid era. Pharmacol Ther. 2022;233: 108019.

Article  CAS  PubMed  Google Scholar 

Strang J, McDonald R, Campbell G, Degenhardt L, Nielsen S, Ritter A, et al. Take-home naloxone for the emergency interim management of opioid overdose: the public health application of an emergency medicine. Drugs. 2019;79(13):1395–418.

Article  PubMed  PubMed Central  Google Scholar 

Stam NC, Cogger S, Schumann JL, Weeks A, Roxburgh A, Dietze PM, et al. The onset and severity of acute opioid toxicity in heroin overdose cases: a retrospective cohort study at a supervised injecting facility in Melbourne, Australia. Clin Toxicol. 2022;6:1–8.

Google Scholar 

Strang J, Darke S, Hall W, Farrell M, Ali R. Heroin overdose: the case for take-home naloxone. BMJ. 1996;312(7044):1435–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strang J. Take-home naloxone and the prevention of deaths from heroin overdose: pursuing strong science, fuller understanding, greater impact. Eur Addict Res. 2022;28(3):161–75.

Article  PubMed  Google Scholar 

Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand. 2002;46(7):759–70.

Article  CAS  PubMed  Google Scholar 

Dale O. Ethical issues and stakeholders matter. Addiction. 2016;111(4):587–9.

Article  PubMed  Google Scholar 

Strang J, McDonald R, Tas B, Day E. Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures? Addiction. 2016;111(4):574–82.

Article  PubMed  Google Scholar 

Krieter PA, Chiang CN, Gyaw S, McCann DJ. Comparison of the pharmacokinetic properties of naloxone following the use of FDA-approved intranasal and intramuscular devices versus a common improvised nasal naloxone device. J Clin Pharmacol. 2019;59(8):1078–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Olofsen E, van Dorp E, Teppema L, Aarts L, Smith TW, Dahan A, et al. Naloxone reversal of morphine- and morphine-6-glucuronide-induced respiratory depression in healthy volunteers: a mechanism-based pharmacokinetic-pharmacodynamic modeling study. Anesthesiology. 2010;112(6):1417–27.

Article  CAS  PubMed  Google Scholar 

van Dorp E, Yassen A, Sarton E, Romberg R, Olofsen E, Teppema L, et al. Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology. 2006;105(1):51–7.

Article  PubMed  Google Scholar 

Yassen A, Olofsen E, Romberg R, Sarton E, Teppema L, Danhof M, et al. Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. Clin Pharmacol Ther. 2007;81(1):50–8.

Article  CAS  PubMed  Google Scholar 

Strang J, McDonald R, Alqurshi A, Royall P, Taylor D, Forbes B. Naloxone without the needle—systematic review of candidate routes for non-injectable naloxone for opioid overdose reversal. Drug Alcohol Depend. 2016;163:16–23.

Article  CAS  PubMed  Google Scholar 

Krieter P, Chiang N, Gyaw S, Skolnick P, Crystal R, Keegan F, et al. Pharmacokinetic properties and human use characteristics of an FDA-approved intranasal naloxone product for the treatment of opioid overdose. J Clin Pharmacol. 2016;56(10):1243–53.

Article  CAS  PubMed  Google Scholar 

McDonald R, Danielsson Glende O, Dale O, Strang J. International patent applications for non-injectable naloxone for opioid overdose reversal: exploratory search and retrieve analysis of the Patent Scope database. Drug Alcohol Rev. 2018;37(2):205–15.

Article  PubMed  Google Scholar 

Dale O. Pharmacokinetic considerations for community-based dosing of nasal naloxone in opioid overdose in adults. Expert Opin Drug Metab Toxicol. 2022;18(3):203–17.

Article  CAS  PubMed  Google Scholar 

Lewenstein M, Fishman J, inventors; Moprhine derivate. USA patent 3254088; 1966.

Blumberg H, Dayton HB, George M, Rapaport DN. N-allylnoroxynorphone; a potent narcotic antagonist. Fedn Proc Fedn Am Soc. 1961;20:311.

Google Scholar 

Blumberg H, Dayton HB, Wolf PS. Counteraction of narcotic antagonist analgesics by the narcotic antagonist naloxone. Proc Soc Exp Biol Med. 1966;123(3):755–8.

Article  CAS  PubMed  Google Scholar 

WHO. The use of essential drugs. Technical report series. [cited 19th December 2022] 1983. https://www.who.int/publications/i/item/9241206853.

McNicholas LF, Martin WR. New and experimental therapeutic roles for naloxone and related opioid antagonists. Drugs. 1984;27(1):81–93.

Article  CAS  PubMed  Google Scholar 

Sutar R, Sahu S. Pharmacotherapy for dissociative disorders: a systematic review. Psychiatry Res. 2019;281: 112529.

Article  CAS  PubMed  Google Scholar 

Valbrun LP, Zvonarev V. The opioid system and food intake: use of opiate antagonists in treatment of binge eating disorder and abnormal eating behavior. J Clin Med Res. 2020;12(2):41–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Springborg AD, Jensen EK, Kreilgaard M, Petersen MA, Papathanasiou T, Lund TM, et al. High-dose naloxone: effects by late administration on pain and hyperalgesia following a human heat injury model. A randomized, double-blind, placebo-controlled, crossover trial with an enriched enrollment design. PLoS ONE. 2020;15(11): e0242169.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morlion BJ, Mueller-Lissner SA, Vellucci R, Leppert W, Coffin BC, Dickerson SL, et al. Oral prolonged-release oxycodone/naloxone for managing pain and opioid-induced constipation: a review of the evidence. Pain Pract. 2018;18(5):647–65.

Article  PubMed  Google Scholar 

Colucci SV, Perrino PJ, Shram M, Bartlett C, Wang Y, Harris SC. Abuse potential of intravenous oxycodone/naloxone solution in nondependent recreational drug users. Clin Drug Investig. 2014;34(6):421–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Walsh SL, Nuzzo PA, Babalonis S, Casselton V, Lofwall MR. Intranasal buprenorphine alone and in combination with naloxone: abuse liability and reinforcing efficacy in physically dependent opioid abusers. Drug Alcohol Depend. 2016;162:190–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Naloxone. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Naloxone#section=3D-Conformer. Accessed Oct 26 2022.

Hansch C, Hoekman D, Leo A, Zhang L, Li P. The expanding role of quantitative structure-activity relationships (QSAR) in toxicology. Toxicol Lett. 1995;79:45–53. https://doi.org/10.1016/0378-4274(95)03356-p.

Article  CAS  PubMed  Google Scholar 

Balyan R, Hahn D, Huang H, Chidambaran V. Pharmacokinetic and pharmacodynamic considerations in developing a response to the opioid epidemic. Expert Opin Drug Metab Toxicol. 2020;16(2):125–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tam SW. (+)-[3H]SKF 10,047, (+)-[3H]ethylketocyclazocine, mu, kappa, delta and phencyclidine binding sites in guinea pig brain membranes. Eur J Pharmacol. 1985;109(1):33–41.

Article  CAS  PubMed  Google Scholar 

Kanemasa T, Koike K, Takase K, Arai T, Nakamura A, Morioka Y, et al. Pharmacological profile of naldemedine, a peripherally acting μ-opioid receptor antagonist: comparison with naloxone and naloxegol. J Pharmacol Exp Ther. 2020;373(3):438–44.

Article  CAS  PubMed  Google Scholar 

Moss RB, Pryor MM, Baillie R, Kudrycki K, Friedrich C, Reed M, et al. Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level. PLoS ONE. 2020;15(6): e0234683.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cassel JA, Daubert JD, DeHaven RN. [(3)H]Alvimopan binding to the micro opioid receptor: comparative binding kinetics of opioid antagonists. Eur J Pharmacol. 2005;520(1–3):29–36.

Article  CAS  PubMed  Google Scholar 

Melichar JK, Nutt DJ, Malizia AL. Naloxone displacement at opioid receptor sites measured in vivo in the human brain. Eur J Pharmacol. 2003;459(2–3):217–9.

Article  CAS  PubMed  Google Scholar 

Glass PS, Jhaveri RM, Smith LR. Comparison of potency and duration of action of nalmefene and naloxone. Anesth Analg. 1994;78(3):536–41.

Article  CAS  PubMed